NO3054950T3 - - Google Patents

Info

Publication number
NO3054950T3
NO3054950T3 NO14726443A NO14726443A NO3054950T3 NO 3054950 T3 NO3054950 T3 NO 3054950T3 NO 14726443 A NO14726443 A NO 14726443A NO 14726443 A NO14726443 A NO 14726443A NO 3054950 T3 NO3054950 T3 NO 3054950T3
Authority
NO
Norway
Application number
NO14726443A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3054950T3 publication Critical patent/NO3054950T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO14726443A 2014-05-09 2014-05-09 NO3054950T3 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000028 WO2015171004A1 (en) 2014-05-09 2014-05-09 (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine

Publications (1)

Publication Number Publication Date
NO3054950T3 true NO3054950T3 (ja) 2017-12-30

Family

ID=50819930

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14726443A NO3054950T3 (ja) 2014-05-09 2014-05-09

Country Status (28)

Country Link
US (2) US20170145015A1 (ja)
EP (1) EP3054950B1 (ja)
JP (1) JP2017514884A (ja)
KR (1) KR102232198B1 (ja)
CN (1) CN106413714A (ja)
AU (1) AU2014393489B2 (ja)
CA (1) CA2948596C (ja)
CY (1) CY1119522T1 (ja)
DK (1) DK3054950T3 (ja)
EC (1) ECSP16086232A (ja)
ES (1) ES2649491T3 (ja)
HR (1) HRP20171650T1 (ja)
HU (1) HUE035030T2 (ja)
IL (1) IL248854B (ja)
LT (1) LT3054950T (ja)
MA (1) MA39448B1 (ja)
MX (1) MX368735B (ja)
NO (1) NO3054950T3 (ja)
NZ (1) NZ726131A (ja)
PH (1) PH12016502236A1 (ja)
PL (1) PL3054950T3 (ja)
PT (1) PT3054950T (ja)
RS (1) RS56590B1 (ja)
RU (1) RU2695607C2 (ja)
SI (1) SI3054950T1 (ja)
TN (1) TN2016000497A1 (ja)
UA (1) UA116499C2 (ja)
WO (1) WO2015171004A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3054950T3 (en) 2014-05-09 2017-11-06 Tecnimede-Sociedade Tecnico-Medicinal S A (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CA2948595C (en) * 2014-05-09 2021-07-13 Tecnimede Sociedade Tecnico-Medicinal S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
KR102421013B1 (ko) 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
WO2019241564A1 (en) * 2018-06-13 2019-12-19 Children's Medical Center Corporation Biomarkers of neuropathic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030633A2 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
BR0317747A (pt) * 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
US20070043030A1 (en) * 2003-09-15 2007-02-22 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
HUE035071T2 (en) * 2014-05-09 2018-05-02 Tecnimede Sociedade Tecnico Medicinal S (S) -pirlindole and its pharmaceutically acceptable salts for use in medicine
DK3054950T3 (en) 2014-05-09 2017-11-06 Tecnimede-Sociedade Tecnico-Medicinal S A (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CA2948595C (en) * 2014-05-09 2021-07-13 Tecnimede Sociedade Tecnico-Medicinal S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine

Also Published As

Publication number Publication date
RU2016148182A (ru) 2018-06-13
HUE035030T2 (en) 2018-05-02
UA116499C2 (uk) 2018-03-26
CA2948596A1 (en) 2015-11-12
JP2017514884A (ja) 2017-06-08
ECSP16086232A (es) 2017-02-24
EP3054950B1 (en) 2017-08-02
RS56590B1 (sr) 2018-02-28
MA39448B1 (fr) 2019-12-31
TN2016000497A1 (en) 2018-04-04
PL3054950T3 (pl) 2018-02-28
CA2948596C (en) 2021-06-08
US20180111944A1 (en) 2018-04-26
KR102232198B1 (ko) 2021-03-26
ES2649491T3 (es) 2018-01-12
US20170145015A1 (en) 2017-05-25
KR20170003567A (ko) 2017-01-09
AU2014393489B2 (en) 2020-01-02
HRP20171650T1 (hr) 2017-12-15
EP3054950A1 (en) 2016-08-17
SI3054950T1 (sl) 2017-12-29
NZ726131A (en) 2018-12-21
CY1119522T1 (el) 2018-03-07
US10533012B2 (en) 2020-01-14
IL248854B (en) 2020-05-31
MX368735B (es) 2019-10-14
RU2695607C2 (ru) 2019-07-24
MX2016014701A (es) 2017-05-23
PH12016502236A1 (en) 2017-02-06
AU2014393489A1 (en) 2016-11-24
WO2015171004A1 (en) 2015-11-12
MA39448A1 (fr) 2018-08-31
RU2016148182A3 (ja) 2018-06-13
CN106413714A (zh) 2017-02-15
PT3054950T (pt) 2017-11-29
LT3054950T (lt) 2017-11-27
DK3054950T3 (en) 2017-11-06
IL248854A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
BR112016023120A2 (ja)
BR112016022558A2 (ja)
BR112016017659A2 (ja)
BR112016025899A2 (ja)
BR112016021137A2 (ja)
BR112016023155A2 (ja)
BR112016016595A2 (ja)
BR112016017519A2 (ja)
JP1543981S (ja)
BR112016021718A2 (ja)
BR112016019697A2 (ja)
BR112016016558A2 (ja)
BR112016019459A2 (ja)
BR112016021673A2 (ja)
JP1516939S (ja)
BR112016019583A2 (ja)
AP2016009666A0 (ja)
BR112016022436A2 (ja)
BR112016018578A2 (ja)
BR112016023360A2 (ja)
BR112016021345A2 (ja)
BR112016017960A2 (ja)
BR112016019538A2 (ja)
BR112016021578A2 (ja)
BR112016018954A2 (ja)